Partnership aims to accelerate global development and commercialization plans for tildacerfont to address worldwide unmet medical need in congenital adrenal hyperplasia (CAH)
Deal advances strategy to partner tildacerfont commercial rights outside the United States
Spruce to receive $15 million upfront payment plus development and commercial milestone payments in addition to tiered double-digit royalties on net sales in Japan
https://finance.yahoo.com/news/spruce-biosciences-kaken-pharmaceutical-announce-210000146.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.